[1]
|
Fuster, V. (2009) The CVD Paradox: Mortality vs. Prevalence. Nature Reviews Cardiology, 6, 669. https://doi.org/10.1038/nrcardio.2009.187
|
[2]
|
Khanji, M.Y., Bicalho, V.S., van Waardhuizen, C.N., Ferket, B.S., Petersen, S.E. and Myriam Hunink, M. (2016) Cardiovascular Risk Assessment: A Systematic Review of Guidelines. Annals of Internal Medicine, 165, 713-722.
|
[3]
|
Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M. Das, S.R. and de Ferranti, S. (2016) American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report from the American Heart Association. Circulation, 133, e38-360.
https://doi.org/10.1161/CIR.0000000000000350
|
[4]
|
Libby, P. (2005) The Forgotten Majority: Unfinished Business in Cardiovascular Risk Reduction. Journal of the American College of Cardiology, 46, 1225-1228.
https://doi.org/10.1016/j.jacc.2005.07.006
|
[5]
|
Kern, M.J. and Meier, B. (2001) Evaluation of the Culprit Plaque and the Physiological Significance of Coronary Atherosclerotic Narrowings. Circulation, 103, 3142-3149.
https://doi.org/10.1161/01.CIR.103.25.3142
|
[6]
|
Arbab-Zadeh, A., Nakanano, M., Virmani, R. and Fuster, V. (2012) Acute Coronary Events. Circulation, 125, 1147-1156.
https://doi.org/10.1161/CIRCULATIONAHA.111.047431
|
[7]
|
Chaitman,j B.R., Fisher, L.D., Bourassa, M.G., Davis, K., Rogers, W.J., Maynard. C., et al. (1981) Effect of Coronary Bypass Surgery on Survival Patterns in Subsets of Patients with Left Main Coronary Artery Disease: Report of the Collaborative Study in Coronary Artery Surgery (CASS). American Journal of Cardiology, 48, 765-777
https://doi.org/10.1016/0002-9149(81)90156-9
|
[8]
|
Pitt, B., Waters, D., Brown, W.V., van Boven, A.J., Schwartz, L., Title, L.M., et al. (1999) Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease. Atorvastatin versus Revascularization Treatment Investigators. The New England Journal of Medicine, 341, 70-76.
https://doi.org/10.1056/NEJM199907083410202
|
[9]
|
Stone, N., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al. (2014) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63, 2889-2934.
https://doi.org/10.1016/j.jacc.2013.11.002
|
[10]
|
Steenhuysen, J. and Berkrot, B. (2014) New Data Fuels Doctors’ Demands to Rewrite U.S. Heart Guidelines. Reuters.
http://in.reuters.com/article/2014/11/21/us-health-heart-cholesterol-idUSKCN0J50E320141121
|
[11]
|
Nicholls, S.J., Sipahi, I. and Tuzcu, E.M. (2006) Assessment of Progression and Regression of Coronary Atherosclerosis by Intravascular Ultrasound. A New Paradigm Shift? Revista Espanola de Cardiología, 59, 57-66. https://doi.org/10.1157/13083650
|
[12]
|
Nicholls, S.J., Ballantyne, C.M., Barter, P.J., Chapman, J., Erbel, R.M., Libby, P., et al. (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. The New England Journal of Medicine, 365, 2078-2087.
https://doi.org/10.1056/NEJMoa1110874
|
[13]
|
Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al. (2005) Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. Lancet, 366, 1267-1278. https://doi.org/10.1016/S0140-6736(05)67394-1
|
[14]
|
Zaragoza, C., Gomez-Guerrero, C., Martin-Ventura, J.L., Blanco-Colio, L., Lavin, B., Mallavia, B., et al. (2011) Animal Models of Cardiovascular Diseases. Journal of Biomedicine and Biotechnology, 2011, Article ID: 497841.
https://doi.org/10.1155/2011/497841
|
[15]
|
Aliev, G. and Burnstock, G. (1998) Watanabe Rabbits with Heritable Hypercholesterolaemia: A Model of Atherosclerosis. Histology and Histopathology, 3, 797-817.
|
[16]
|
Goldstein, J.L. and Brown, M.S. (2009) History of Discovery: The LDL Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 431-438.
https://doi.org/10.1161/ATVBAHA.108.179564
|
[17]
|
Bilheimer, D.W., Goldstein, J.L., Grundy, S.M., Starzl, T.E. and Brown, M.S. (1984) Liver Transplantation to Provide Low-Density-Lipoprotein Receptors and Lower Plasma Cholesterol in a Child with Homozygous Familial Hypercholesterolemia. The New England Journal of Medicine, 311, 1658-1664.
https://doi.org/10.1056/NEJM198412273112603
|
[18]
|
Budoff, M.J., Young, R., Burke, G., Carr, J.J., Detrano, R.C., et al. (2018) Ten-Year Association of Coronary Aratery Calcium with Atherosclerotic Cardiovascular Disease (ASCVD) Events: The Multi-Ethnic Study of Atherosclerosis (MESA). European Heart Journal, 39, 2401-2408.
|
[19]
|
Nioi, P., Sigurdsson, A., Thorleifsson, G., Helgason, H., Agustsdottir, A.B., Norddahl, G.L., et al. (2016) Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease. The New England Journal of Medicine, 374, 2131-2134.
https://doi.org/10.1056/NEJMoa1508419
|
[20]
|
Ference, B.A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K.K., Mewada, A., et al. (2012) Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis. Journal of the American College of Cardiology, 60, 2631-2639. https://doi.org/10.1016/j.jacc.2012.09.017
|
[21]
|
Ference, B.A., et al. (2015) Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or both: A 2 × 2 Factorial Mendelian Randomization Study. Journal of the American College of Cardiology, 65, 1552-1561. https://doi.org/10.1016/j.jacc.2015.02.020
|
[22]
|
Jaiswal, S., Natarajan, P., Silver, A.J., Gibson, C.J., Bick, A.G., Shvartz, E., et al. (2017) Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. The New England Journal of Medicine, 377, 111-121.
https://doi.org/10.1056/NEJMoa1701719
|
[23]
|
Carr, J.J., Jacobs, D.R., Terry, J.G., Shay, C.M., Sidney, S., Liu, K., et al. (2016) Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years with Incident Coronary Heart Disease and Death. JAMA Cardiology, 2, 391-399.
|
[24]
|
McClelland, R.L., Jorgensen, N.W., Budoff, M., Blaha, M.J., Post, W.S., Kronmal, R.A., et al. (2015) 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). Journal of the American College of Cardiology, 66, 1643-1653. https://doi.org/10.1016/j.jacc.2015.08.035
|
[25]
|
Keraliya, A. and Blankstein, R. (2017) Regression of Coronary Atherosclerosis with Medical Therapy. The New England Journal of Medicine, 376, 1370.
https://doi.org/10.1056/NEJMicm1609054
|
[26]
|
Brown, G., Albers, J.J., Fisher, L.D., Schaefer, S.M., Lin, J.T., Kaplan, C., et al. (1990) Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B. The New England Journal of Medicine, 323, 1289-1298. https://doi.org/10.1056/NEJM199011083231901
|
[27]
|
Jensen, L.O., Thayssen, P., Pedersen, K.E., Stender, S. and Haghfelt, T. (2004) Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study. Circulation, 110, 265-270.
https://doi.org/10.1161/01.CIR.0000135215.75876.41
|
[28]
|
Nicholls, S.J., Tuzcu, E.M., Sipahi, I., Grasso, A.W., Schoenhagen, P., Hu, T., Wolski, K., et al. (2007) Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA, 297, 499-508.
https://doi.org/10.1001/jama.297.5.499
|
[29]
|
Nissen, S.E., Nicholls, S.J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., et al. (2008) Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial. JAMA, 299, 1561-1573. https://doi.org/10.1001/jama.299.13.1561
|
[30]
|
Stegman, B., Puri, R., Cho, L., Shao, M., Ballantyne, C.M., Barter, P.J., Chapman, M.J., et al. (2014) High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights from SATURN. Diabetes Care, 37, 3114-3120. https://doi.org/10.2337/dc14-1121
|
[31]
|
Silverman, M.G., Ference, B.A., Im, K., Wiviott, S.D., Giugliano, R.P., Grundy, S.M., Braunwald, E. and Sabatine, M.S. (2016) Association between Lowering LDL-C and Cardiovascular Risk Reduction among Different Therapeutic Interventions: A Systematic Review and Meta-Analysis. JAMA, 316, 1289-1297.
https://doi.org/10.1001/jama.2016.13985
|
[32]
|
Schade, D.S., Cavanaugh, B., Ramo, B. and Eaton, R.P. (2016) The Application of the LDL Principle. World Journal of Cardiovascular Diseases, 6, 109-125.
https://doi.org/10.4236/wjcd.2016.65012
|
[33]
|
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A., Kinch, L., Grishin, N.V., Horton, J.D., et al. (2006) Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote. The American Journal of Human Genetics, 79, 514-523. https://doi.org/10.1086/507488
|
[34]
|
Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722.
https://doi.org/10.1056/NEJMoa1615664
|
[35]
|
O’Keefe, J.H. (2004) Optimal Low-Density Lipoprotein Is 50 to 70 mg/dl: Lower Is Better and Physiologically Normal. Journal of the American College of Cardiology, 43, 2142-2146. https://doi.org/10.1016/j.jacc.2004.03.046
|
[36]
|
Wilmot, K.A., O’Flaherty, M., Capewell, S., Ford, E.S. and Vaccarino, V. (2015) Coronary Heart Disease Mortality Declines in the United States from 1979 through 2011: Evidence for Stagnation in Young Adults, Especially Women. Circulation, 132, 997-1002. https://doi.org/10.1161/CIRCULATIONAHA.115.015293
|
[37]
|
Kusters, D.M., Avis, H.J., de Groot, E., et al. (2014) Ten-Year Follow-Up after Initiation of Statin Therapy in Children with Familial Hypercholesterolemia. JAMA, 312, 1055-1057. https://doi.org/10.1001/jama.2014.8892
|
[38]
|
Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E.H., et al. (2012) The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials. The Lancet, 380, 581-590.
https://doi.org/10.1016/S0140-6736(12)60367-5
|
[39]
|
Berry, J.D., Lloyd-Jones, D.M., Garside, D.B. and Greenland, P. (2007) Framingham Risk Score and Prediction of Coronary Heart Disease Death in Young Men. American Heart Journal, 154, 80-86. https://doi.org/10.1016/j.ahj.2007.03.042
|
[40]
|
Greenland, P., LaBree, L., Azen, S.P., Doherty, T.M. and Detrano, R.C. (2004) Coronary Artery Calcium Score Combined with Framingham Score for Risk Prediction in Asymptomatic Individuals. JAMA, 291, 210-215.
https://doi.org/10.1001/jama.291.2.210
|
[41]
|
Nasir, K., Rubin, J., Blaha, M.J., Shaw, L.J., Blankstein, R., Rivera, J.J., Khan, A.N., et al. (2012) Interplay of Coronary Artery Calcification and Traditional Risk Factors for the Prediction of All-Cause Mortality in Asymptomatic Individuals. Circulation: Cardiovascular Imaging, 5, 467-473.
https://doi.org/10.1161/CIRCIMAGING.111.964528
|
[42]
|
Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. The New England Journal of Medicine, 340, 115-126.
|
[43]
|
Catapano, A.L., Graham, I., De Backer, G., et al. (2016) ESC/EAS Guidelines for the Management of Dyslipidemias. European Heart Journal, 37, 2999-3058.
https://doi.org/10.1093/eurheartj/ehw272
|
[44]
|
Hayward, R.S.A. (1997) Clinical Practice Guidelines on Trial. CMAJ, 156, 1725-1727.
|
[45]
|
Pagidipati, N.J., Navar, A.M., Mulder, H., Sniderman, A.D., Peterson, E.D. and Pencina, M.J. (2017) Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs. the ACC/AHA Guidelines. JAMA, 317, 1563-1567.
https://doi.org/10.1001/jama.2017.3416
|
[46]
|
Pencina, M.J., Navar-Boggan, A.M., D’Agostino, R.B., Williams, K., Neely, B., Sniderman, A.D. and Peterson, E.D. (2014) Application of New Cholesterol Guidelines to a Population-Based Sample. The New England Journal of Medicine, 370, 1422-1431. https://doi.org/10.1056/NEJMoa1315665
|
[47]
|
Lazar, L.D., Pletcher, M.J., Coxson, P.G., Bibbins-Domingo, K. and Goldman, L. (2011) Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era. Circulation, 124, 146-153.
https://doi.org/10.1161/CIRCULATIONAHA.110.986349
|
[48]
|
AHA Committee; Stroke Statistics Subcommittee (2016) Heart Disease and Stroke Statistics—2016 Update: A Report from the American Heart Association. Circulation, 133, e38-e360. https://doi.org/10.1161/CIR.0000000000000350
|
[49]
|
Cabana, M.D., Rand, C.S., Powe, N.R., Wu, A.W., Wilson, M.H., Abboud, P.-A.C., et al. (1999) Why Don’t Physicians Follow Clinical Practice Guidelines? A Framework for Improvement. JAMA, 282, 1458-1465.
https://doi.org/10.1001/jama.282.15.1458
|
[50]
|
Bothwell, L.E., Greene, J.A., Podolsky, S.H. and Jones, D.S. (2016) Assessing the Gold Standard—Lessons from the History of RCTs. The New England Journal of Medicine, 374, 2175-2181. https://doi.org/10.1056/NEJMms1604593
|